The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2015 | Considerations for the early treatment of multiple myeloma
Philippe Moreau
• 11 Apr 2015
At the Myeloma 2015 meeting, Prof Philippe Moreau (Centre Hospitalier Universitaire de Nantes, France) discusses prospective treatment strategies for early-stage multiple myeloma (MM). Research suggests that patients with the highest risk of MM should be treated like patients with symptomatic disease. For smoldering MM, research on a new number of treatment options is ongoing.
